Sort   by:  
 Page size 
ProteomicsPhosphoproteomic analysis in Glioblastoma in response to AZD1775
The aim of this study was to characterize phosphoproteome in response to AZD1775 in patient derived xenografts (PDX) lines and clinical specimens in glioblastoma. Tyrosine and motif specific serine and threonine phosphorylation were measured using quantitative LC-MS/MS based on TMT labeling.
ORGANISM(S): Homo sapiens (Human) 
2022-10-13 | PXD018782 | Pride
Phosphoproteomics Azd1775 Glioblastoma 
GenomicsRibosome profiling following AZD1775 treatment
Ribosome profiling following AZD1775 10 hour treatment in RPE1 TP53- cells
PRJEB93983 | ENA
UnknownPhase 0 Trial of AZD1775 in First-Recurrence Glioblastoma Patients.
Not available
S-EPMC6865048 | biostudies-literature
UnknownWee1 Kinase Inhibitor AZD1775 Effectively Sensitizes Esophageal Cancer to Radiotherapy.
Not available
S-EPMC7367716 | biostudies-literature
GenomicsIdentifying and overcoming a mechanism of resistance to Wee1 kinase inhibitor AZD1775 in high grade serous ovarian cancer cells (ES-2)
Identifying and overcoming a mechanism of resistance to Wee1 kinase inhibitor AZD1775 in high grade serous ovarian cancer cells (ES-2)
PRJNA595945 | ENA
ProteomicsTime-course SILAC proteomics to determine the response to WEE1i in RPE-1 WT vs EIF2A-KO RPE-1 cells
AZD1775 is an ATP-competitive inhibitor of WEE1 protein kinase. Inhibition of WEE1 causes hyperactivation of CDK1 and CDK2, which leads to premature mitosis and DNA replication stress. AZD1775 has been evaluated in patients with relapsed high grade serous ovarian cancer (HGSOC) and has shown promisi...
ORGANISM(S): Homo sapiens (Human) 
2025-10-07 | PXD054741 | Pride
Human ovarian wee1 eif2a hgsoc 
UnknownDual Targeting of WEE1 and PLK1 by AZD1775 Elicits Single Agent Cellular Anticancer Activity.
Not available
S-EPMC5551971 | biostudies-literature
GenomicsIdentifying and overcoming a mechanism of resistance to Wee1 kinase inhibitor AZD1775 in high grade serous ovarian cancer cells (OVCAR8)
Identifying and overcoming a mechanism of resistance to Wee1 kinase inhibitor AZD1775 in high grade serous ovarian cancer cells (OVCAR8)
PRJNA595516 | ENA
TranscriptomicsDual role of the unfolded protein response in the therapeutic effect of AZD1775 on TP53 mutant high grade serous ovarian cancer
we demonstrate that the WEE1 inhibitor AZD1775 triggers endoplasmic reticulum (ER) stress and activates the PERK and IRE1α branches of the unfolded protein response (UPR) in TP53 mutant HGSOC cells. Upon AZD1775 treatment, PERK facilitates apoptotic signaling in these cells via activating CHOP, wher...
ORGANISM(S): Homo sapiens 
2021-02-10 | GSE166417 | GEO
UnknownAZD1775 sensitizes T cell acute lymphoblastic leukemia cells to cytarabine by promoting apoptosis over DNA repair.
Not available
S-EPMC4695040 | biostudies-literature
Sort   by:  
 Page size